PTC Therapeutics


Based: South Plainfield, NJ
Raised: $23 million
Investors: Bay City Capital, Delphi Ventures, HBM Partners, Vulcan Capital

The scoop: PTC went two years without a round. By this point, PTC chief Stuart Peltz had hoped to be a public company. But that goal has proved elusive. A few days ago the biotech announced that it had raised $30 million, and the NVCA notes that its filings indicate that it has set a goal of $40 million. The $23 million was what it garnered for its bank account in the first half. The money is being used to finance late-stage development of ataluren, PTC's lead program for Duchenne/Becker muscular dystrophy as well as cystic fibrosis, which has had a long and often difficult passage in the clinic. PTC was named a Fierce 15 company in 2007.

PTC Therapeutics

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.